According to GlobalData’s medical device pipeline database, 257 Transcatheter Heart Valves devices are in various stages of development globally. GlobalData’s report Transcatheter Heart Valves provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 193 are in active development, while the remaining 71 are in an inactive stage of development. There are 84 products in the early stages of development, and the remaining 109 are in the late stages of development.
Transcatheter heart valves are synthetic valves made from biological tissues surrounded by a steel, cobalt-chromium, or nitinol stent. Transcatheter heart valves can be either balloon expandable or self-expandable. One unit refers to one Transcatheter Heart Valve. Transcatheter heart valve includes Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Implantation (TMVI), Transcatheter Pulmonary Valve Replacement (TPVR) and Transcatheter Mitral Valve Repair (TMVR).
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Transcatheter Heart Valves pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Transcatheter Heart Valves devices. Overall, most of these Transcatheter Heart Valves pipeline devices are being developed by private entities.
Key players involved in the active development of Transcatheter Heart Valves include Edwards Lifesciences, Jenscare Scientific, NewMed Medical, Peijia Medical, Venus Medtech Hangzhou, Lepu Medical Technology (Beijing), MicroPort CardioFlow Medtech, Boston Scientific, Colibri Heart Valve and Polyvascular.
For a complete picture of the developmental pipeline for Transcatheter Heart Valves devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.